<DOC>
	<DOCNO>NCT00811174</DOCNO>
	<brief_summary>Octagam human normal immunoglobulin ( IGIV ) solution intravenous administration . Octagam 5 % currently register 60 country . This study evaluate efficacy , safety kinetics Octagam 10 % replacement therapy primary immunodeficiency disease .</brief_summary>
	<brief_title>Efficacy , Safety Kinetics Study Octagam 10 % Primary Immunodeficiency Diseases</brief_title>
	<detailed_description>The primary objective study investigate safety Octagam 10 % replacement therapy PID compare pharmacokinetic profile Octagam 10 % previously use Octagam 5 % . The secondary objective investigate efficacy Octagam 10 % replacement therapy PID monitoring rate occurence serious bacterial infection , rate infection , trough ( pre-next-dose ) level total serum IgG IgG subclass ( IgG1 , IgG2 , IgG3 IgG4 ) , trough ( pre-next-dose ) level select antigen specific antibody , use antibiotic , rate absence school/ work , number day hospital .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Confirmed diagnosis primary immunodeficiency ( acc . WHO ) Previous treatment commercial Octagam 5 % every 34 week least 6 infusion interval Documented IgG trough level two previous infusion enrollment value least 5.5 g/L Acute infection require intravenous antibiotic treatment within two week screen Exposure blood blood product derivative commercially available Octagam 5 % , within past 3 month History hypersensitivity blood plasma derive product Requirement routine premedication IGIV treatment History congenital impairment pulmonary function Severe liver function impairment Severe renal function impairment predisposition acute renal failure History autoimmune haemolytic anaemia History diabetes mellitus Congestive heart failure NYHA III IV Noncontrolled arterial hypertension History DVT thrombotic complication IGIV treatment Known infection HIV , HCV HBV Treatment steroid , immunosuppressive immunomodulatory drug Planned vaccination study period Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>